AVB Biotechnology has established its focus on therapeutic technology development around "Unmet Medical Needs."The biotechnological target modeling strategy is executed through an objective matrix encompassing multidimensional parameters such as global health crises, mortality rates, the limitations of current therapeutic options, global dissemination risk, and the socio-economic cost of devastation. In this regard, corporate priorities have been structured into prioritized phases characterized by a sequence of pathophysiological and etiological alignment, beginning with areas that present the highest risk worldwide and receive the most intensive scientific resource allocation, which also represent the priority domains highlighted by regulatory health authorities.

► Phase 1: Global Acute Crisis Management

• Focus Area: Lethal pathogens, epidemics, pandemics, and treatment-resistant acute infection processes.

• Strategic Rationale:

  • Highest Regulatory Priority: It lies at the core of the absolute and primary "unmet medical need" class, addressed with the highest level of urgency by global health authorities (FDA, EMA).

  • Historical and Current Mortality Burden: Epidemics and pandemics have caused hundreds of millions of fatalities throughout history; today, acute viral, bacterial, and fungal infections remain among the largest drivers of global mortality.

  • Macroeconomic Threat and "Disease X": Potential pandemic scenarios (Disease X) featured in World Health Organization (WHO) projections impose an unsustainable burden on the global economy, with trillions of dollars in therapeutic costs.

  • Global R&D and Funding Intensity: Biosecurity and acute outbreak control represent the highest-priority global scientific focus, attracting hundreds of billions of dollars in international funds, government incentives, and biotechnology investments annually.

► Phase 2: Cardiovascular System Management

• Focus Area: Cardiovascular diseases (ischemic heart diseases, heart failure, and vascular pathologies).

• Strategic Rationale:

  • Highest Global Mortality: According to World Health Organization data, cardiovascular diseases are the number one cause of death worldwide, with an average of over 30 million fatalities annually.

  • Unsustainable Financial and Indirect Costs: Surgical interventions, intensive care processes, and chronic loss of productivity (DALY) render this field the single largest source of macroeconomic pressure on the global healthcare economy.

  • Regulatory Definition of Priority: Due to the high risk of sudden death and functional losses that dramatically reduce the quality of life, these pathologies are classified as primary "unmet medical needs" by authorities (FDA, EMA).

  • Global R&D and Funding Intensity: The cardiovascular ecosystem is one of the sectors where research budgets are most intensively allocated within the biotechnology domain. Targeting this focus means integrating into a shared global vision where billions of dollars in resources are managed annually.

► Phase 3: Gene Expression Disorders, Autoimmune, and Immunological Management

• Focus Area: Chronic gene expression disorders, autoimmune and autoinflammatory diseases, metabolic and hormonal dysregulations (FMF, Crohn's, Diabetes, Obesity, Hormonal Disorders, and Severe Allergies).

• Strategic Rationale:

  • Lifelong Chronic Disease Burden: Diseases in this group typically onset at an early age and persist throughout life, leading to permanent systemic damage and systematically reducing patients' Quality of Life (QoL).

  • Regulatory Definition of a "Persistent Clinical Gap": These pathologies, characterized by a limited probability of full recovery (cure) and persistent gaps in clinical management, are positioned within the most critical "unmet medical needs" lists by global authorities (FDA, EMA).

  • High DALY Loss and Socio-Economic Cost: Lifelong clinical follow-up, recurrent hospitalizations, and continuous care needs generate an unsustainable indirect economic burden on both families and health insurance systems, as well as a significant loss of Disability-Adjusted Life Years (DALY).

  • Focus of Global Biotechnology Investments: Research targeting immunology, endocrinology, and cellular signaling mechanisms stands as one of the primary focal points in modern medicine, where the largest R&D budgets, international fund flows, and global academic mobilization are concentrated.

► Phase 4: Epigenetic Restoration

• Focus Area: Cellular rejuvenation, reversal of cellular senescence, and chronic neurodegenerative processes (Alzheimer's, Parkinson's, etc.).

• Strategic Rationale:

  • Objective of Biological Restoration: Preserving the cellular identity of the organism, the objective is to reset epigenetic and transcriptomic profiles to the "post-adolescent homeostatic baseline," which represents the biological peak.

  • Global Demographic and Economic Pressure: The aging global population and the consequent development of chronic functional losses constitute the largest long-term financial burden on the modern healthcare economy and social security systems.

  • Future Vision of Authorities and the Scientific Community: Global regulators and institutes have begun to position aging not merely as an inevitable chronological process, but as a "systemic functional insufficiency"that must be intervened in, slowed, and potentially reversed.

  • Highest Value-Added Biotechnology Sector: Healthy lifespan extension (longevity) and cellular restoration studies represent the highest scientific tier, attracting the focus of the most visionary global funds, massive investments, and pioneering academic research worldwide.